Urology
Volume 68, Issue 6 , Pages 1280-1283 , December 2006

Prostate cancer and schizophrenia

  • E. Fuller Torrey

      Affiliations

    • Corresponding Author InformationReprint requests: E. Fuller Torrey, M.D., Stanley Medical Research Institute, 8401 Connecticut Avenue, Suite 200, Chevy Chase, MD 20815

Received 9 March 2006 ,Accepted 11 August 2006.

References 

  1. Fox BH. Cancer death risk in hospitalized mental patients. Science. 1978;201:966–968
  2. Mortensen PB. The incidence of cancer in schizophrenic patients. J Epidemiol Commun Health. 1989;43:43–47
  3. Lichtermann D, Ekelund J, Pukkala E, et al. Incidence of cancer among persons with schizophrenia and their relatives. Arch Gen Psychiatry. 2001;58:573–578
  4. Goldacre MJ, Kurina LM, Wotton CJ, et al. Schizophrenia and cancer: an epidemiological study. Br J Psychiatry. 2005;187:334–338
  5. Grinshpoon A, Barchana M, Ponizovsky A, et al. Cancer in schizophrenia: is the risk higher or lower?. Schizophr Res. 2005;73:333–341
  6. Dalton SO, Mellemkjaer , Thomassen L, et al. Risk for cancer in a cohort of patients hospitalized for schizophrenia in Denmark, 1969–1993. Schizophr Res. 2005;75:315–324
  7. Barak Y, Achiron A, Mandel M, et al. Reduced cancer incidence among patients with schizophrenia. Cancer. 2005;104:2817–2821
  8. Nakane Y, Ohta Y. The example of linkage with a cancer register. In:  ten Horn GHMM,  Giel R,  Gulbinat WH, et al. editor. Psychiatric Case Registers in Public Health: A Worldwide Inventory 1960–1985. Amsterdam: Elsevier Science Publishers BV; 1986;p. 240–245
  9. Gulbinat W, Dupont A, Jablensky A, et al. Cancer incidence of schizophrenic patients: results of record linkage studies in three countries. Br J Psychiatry. 1992;161(suppl 18):75–85
  10. Lawrence D, Holman CDJ, Jablensky AV, et al. Excess cancer mortality in Western Australian psychiatric patients due to higher case fatality rates. Acta Psychiatr Scand. 2000;101:382–388
  11. Cohen ME, Dembling B, Schorling JB. The association between schizophrenia and cancer: a population-based mortality study. Schizophr Res. 2002;57:139–146
  12. Torrey EF, Yolken RH. The schizophrenia–rheumatoid arthritis connection: infectious, immune, or both?. Brain Behav Immun. 2001;15:401–410
  13. Mortensen PB. Neuroleptic medication and reduced risk of prostate cancer in schizophrenic patients. Acta Psychiatr Scand. 1992;85:390–393
  14. Csatary LK. Chlorpromazines and cancer. Lancet. 1972;2:338–339
  15. Driscoll JS, Melnick NR, Quinn FR, et al. Psychotropic drugs as potential antitumor agents: a selective screening study. Cancer Treat Rep. 1978;62:45–59
  16. Nordenberg J, Fenig E, Landau M, et al. Effects of psychotropic drugs on cell proliferation and differentiation. Biochem Pharmacol. 1999;58:1229–1236
  17. Carrillo JA, Benítez J. Are antipsychotic drugs potentially chemopreventive agents for cancer?. Eur J Clin Pharmacol. 1999;55:487–488
  18. Park JK, Lee HJ, Kim JW, et al. Differences in p53 gene polymorphisms between Korean schizophrenia and lung cancer patients. Schizophr Res. 2004;67:71–74
  19. Bhui K, Puffet A, Strathdee G. Sexual and relationship problems amongst patients with severe chronic psychoses. Soc Psychiatry Psychiatr Epidemiol. 1997;32:459–467
  20. Fortier P, Mottard J-P, Trudel G, et al. Study of sexuality-related characteristics in young adults with schizophrenia treated with novel neuroleptics and in a comparison group of young adults. Schizophr Bull. 2003;29:559–572

PII: S0090-4295(06)01965-0

doi: 10.1016/j.urology.2006.08.1061

Urology
Volume 68, Issue 6 , Pages 1280-1283 , December 2006

Article Tools